SCHEMBL1975441

SCHEMBL1975441

COc1cc2oc(-c3ccc(O)cc3)cc(=O)c2c(O)c1CCCCCCCCCCCCCO

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.64
MAPT P10636 3/20 0.64
KDM4E B2RXH2 3/20 0.64
ADORA3 P0DMS8 1/20 0.64
APP P05067 4/20 0.57
FLT3 P36888 4/20 0.56
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
MKNK2 Q9HBH9 2/20 0.56
GABRP O00591 2/20 0.56
GABRD O14764 2/20 0.56
GABRA1 P14867 2/20 0.56
GABRB1 P18505 2/20 0.56
GABRG2 P18507 2/20 0.56
GABRB3 P28472 2/20 0.56
GABRA5 P31644 2/20 0.56
GABRA3 P34903 2/20 0.56
GABRA2 P47869 2/20 0.56
GABRB2 P47870 2/20 0.56
GABRA4 P48169 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1975034 1.00 POLB (0.64) POLBMAPTKDM4EADORA3APP
SCHEMBL1976594 0.90 KDM4E (0.59) POLBMAPTKDM4EKMT2AMEN1
SCHEMBL1421590 0.90 KDM4E (0.59) POLBMAPTKDM4EKMT2AMEN1
SCHEMBL1977889 0.88 KDM4E (0.53) POLBMAPTKDM4EADORA3FLT3
SCHEMBL1973575 0.88 KDM4E (0.53) POLBMAPTKDM4EADORA3FLT3
SCHEMBL1974890 0.86 KMT2A (0.63) POLBMAPTKDM4EADORA3APP
SCHEMBL1975145 0.86 KMT2A (0.63) POLBMAPTKDM4EADORA3APP
SCHEMBL1975096 0.85 ABCB1 (0.47) POLBMAPTKDM4EADORA3FLT3
SCHEMBL1974901 0.85 ABCB1 (0.47) POLBMAPTKDM4EADORA3FLT3
SCHEMBL1976108 0.83 MEN1 (0.65) POLBMAPTKDM4EADORA3FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AXOGLIA THERAPEUTICS (LU) 2011-06-16 US disclosed
EP-2112145-A1 Chromenone derivatives useful for the treatment of neurodegenerative diseases AxoGlia Therapeutics S.A. (LU) 2009-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES PARK7, CDR2, SNCA POLB 3717/4885MAPT 243/4885KDM4E 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.